tickertape
← golden set

LLY

ELI LILLY & CoHealthcare
10-K for period ending 2025-12-31filed 2026-02-12accession 0000059478-26-000013filing on sec.gov ↗

answer key

fieldSEC valueXBRL conceptprinted on
Total revenue$65.2BRevenuesRevenue
Operating income-not reportednot in this filing's XBRL
Net income attributable to the company$20.6BNetIncomeLossNet income
Diluted EPS$22.95EarningsPerShareDilutedDiluted
Cash and cash equivalents$7.3BCashAndCashEquivalentsAtCarryingValueCash and cash equivalents
Total assets$112.5BAssetsTotal assets · Total liabilities and equity
Total liabilities-not reportednot in this filing's XBRL
Total shareholders' equity attributable to the company$26.5BStockholdersEquityTotal equity
Net cash from operating activities$16.8BNetCashProvidedByUsedInOperatingActivitiesNet Cash Provided by Operating Activities
Net cash from investing activities-$11.0BNetCashProvidedByUsedInInvestingActivitiesNet Cash Used for Investing Activities
Net cash from financing activities-$2.2BNetCashProvidedByUsedInFinancingActivitiesNet Cash Provided by (Used for) Financing Activities

Income statement

table #21 · score 49 vs 26.3 runner-up · in millions
Year Ended December 31,
202520242023
Revenue65,17945,04334,124
Costs, expenses, and other:
Cost of sales11,0528,4187,082
Research and development13,33710,9919,313
Marketing, selling, and administrative11,0948,5947,404
Acquired in-process research and development2,9103,2803,800
Asset impairment, restructuring, and other special charges48486168
Other-net, (income) expense571219(97)
39,44832,36327,570
Income before income taxes25,73112,6806,554
Income taxes5,0912,0901,314
Net income20,64010,5905,240
Earnings per share:
Basic23.0011.765.82
Diluted22.9511.715.80
Shares used in calculation of earnings per share:
Basic897.3900.6900.2
Diluted899.3904.1903.3

Balance sheet

table #23 · score 53.3 vs 20.8 runner-up · in millions
December 31,
20252024
Assets
Current Assets
Cash and cash equivalents7,2683,268
Accounts receivable17,76011,006
Other receivables2,3952,270
Inventories13,7447,589
Prepaid expenses14,3158,341
Other current assets147266
Total current assets55,62932,740
Noncurrent Assets
Investments2,8023,216
Goodwill5,8985,770
Other intangibles, net6,5216,166
Deferred tax assets9,9598,001
Property and equipment, net24,67517,102
Other noncurrent assets6,9925,720
Total assets112,47678,715
Liabilities and Equity
Current Liabilities
Short-term borrowings and current maturities of long-term debt1,6355,117
Accounts payable5,3793,229
Employee compensation2,3752,094
Sales rebates and discounts17,38211,539
Other current liabilities8,4576,397
Total current liabilities35,22828,376
Noncurrent Liabilities
Long-term debt40,86828,527
Long-term income taxes payable5,8754,061
Other noncurrent liabilities3,9703,479
Total noncurrent liabilities50,71336,067
Commitments and Contingencies
Equity
Common stock-no par valueAuthorized shares: 3,200.0Issued shares: 944.8 (2025) and 947.9 (2024)590592
Additional paid-in capital7,3467,439
Retained earnings24,47013,545
Employee benefit trust(3,013)(3,013)
Accumulated other comprehensive loss(2,880)(4,322)
Other equity2231
Total equity26,53514,272
Total liabilities and equity112,47678,715

Cash flow statement

table #25 · score 53 vs 8.3 runner-up · in millions
Year Ended December 31,
202520242023
Cash Flows from Operating Activities
Net income20,64010,5905,240
Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:
Depreciation and amortization1,9971,7671,527
Change in deferred income taxes(1,707)(2,683)(2,341)
Stock-based compensation expense626646629
Gains on sale of product rights(180)(224)(1,879)
Acquired in-process research and development2,9103,2803,800
Other operating activities, net620826319
Other changes in operating assets and liabilities, net of acquisitions and divestitures:
Receivables-(increase) decrease(7,000)(2,155)(2,451)
Inventories-(increase) decrease(4,671)(2,507)(1,425)
Prepaid expenses and other assets-(increase) decrease(6,609)(3,331)(3,453)
Accounts payable and other liabilities-increase (decrease)10,1872,6094,274
Net Cash Provided by Operating Activities16,8138,8184,240
Cash Flows from Investing Activities
Purchases of property and equipment(7,841)(5,058)(3,448)
Proceeds from sales of and distributions from noncurrent investments964374508
Purchases of noncurrent investments(645)(677)(731)
Proceeds from sale of product rights2186011,604
Purchases of in-process research and development(3,008)(3,346)(3,944)
Cash paid for acquisitions, net of cash acquired(661)(948)(1,044)
Other investing activities, net1(248)(98)
Net Cash Used for Investing Activities(10,972)(9,302)(7,153)
Cash Flows from Financing Activities
Dividends paid(5,384)(4,680)(4,069)
Net change in short-term borrowings(4,338)(1,852)4,691
Proceeds from issuance of long-term debt13,16711,4173,959
Repayments of long-term debt(778)(664)-
Purchases of common stock(4,108)(2,500)(750)
Other financing activities, net(772)(491)(335)
Net Cash Provided by (Used for) Financing Activities(2,213)1,2303,496
Effect of exchange rate changes on cash and cash equivalents372(297)169
Net increase in cash and cash equivalents4,000449752
Cash and cash equivalents at beginning of year3,2682,8192,067
Cash and Cash Equivalents at End of Year7,2683,2682,819